Department of Internal Medicine,University Hospital of Salamanca,Salamanca,Spain.
Department of Microbiology,University Hospital of Salamanca,Salamanca,Spain.
Epidemiol Infect. 2018 Dec;146(16):2122-2130. doi: 10.1017/S0950268818002480. Epub 2018 Sep 3.
The objective was to compare the performance of the updated Charlson comorbidity index (uCCI) and classical CCI (cCCI) in predicting 30-day mortality in patients with Staphylococcus aureus bacteraemia (SAB). All cases of SAB in patients aged ⩾14 years identified at the Microbiology Unit were included prospectively and followed. Comorbidity was evaluated using the cCCI and uCCI. Relevant variables associated with SAB-related mortality, along with cCCI or uCCI scores, were entered into multivariate logistic regression models. Global model fit, model calibration and predictive validity of each model were evaluated and compared. In total, 257 episodes of SAB in 239 patients were included (mean age 74 years; 65% were male). The mean cCCI and uCCI scores were 3.6 (standard deviation, 2.4) and 2.9 (2.3), respectively; 161 (63%) cases had cCCI score ⩾3 and 89 (35%) cases had uCCI score ⩾4. Sixty-five (25%) patients died within 30 days. The cCCI score was not related to mortality in any model, but uCCI score ⩾4 was an independent factor of 30-day mortality (odds ratio, 1.98; 95% confidence interval, 1.05-3.74). The uCCI is a more up-to-date, refined and parsimonious prognostic mortality score than the cCCI; it may thus serve better than the latter in the identification of patients with SAB with worse prognoses.
目的是比较更新后的 Charlson 合并症指数 (uCCI) 和经典 CCI (cCCI) 在预测金黄色葡萄球菌菌血症 (SAB) 患者 30 天死亡率方面的性能。前瞻性地纳入微生物学部门鉴定的所有 ⩾14 岁的 SAB 患者,并对其进行随访。使用 cCCI 和 uCCI 评估合并症。将与 SAB 相关死亡率相关的相关变量以及 cCCI 或 uCCI 评分纳入多变量逻辑回归模型。评估并比较了每个模型的总体模型拟合度、模型校准度和预测有效性。共纳入 239 例患者 257 例 SAB 发作(平均年龄 74 岁,65%为男性)。cCCI 和 uCCI 评分的平均值分别为 3.6(标准差 2.4)和 2.9(2.3);161(63%)例 cCCI 评分 ⩾3,89(35%)例 uCCI 评分 ⩾4。65(25%)例患者在 30 天内死亡。在任何模型中,cCCI 评分均与死亡率无关,但 uCCI 评分 ⩾4 是 30 天死亡率的独立因素(比值比,1.98;95%置信区间,1.05-3.74)。uCCI 是一种比 cCCI 更现代、更精细、更简约的预后死亡率评分;因此,它可能比后者更适合识别预后较差的 SAB 患者。